Edvince is a biotech company that develops a new treatment for the management of delayed cerebral ischemic events. This treatment aims to prevent the chain of events leading to brain damage subsequent to a bleed in the brain. The company is currently in the preclinical phase and will initiate its first clinical phase I study in early 2018. Edvince is based at SmiLe Incubator in Lund and is owned by its Lars Edvinsson (founder), Krankajen Group AB, LMK Forward AB, Almi Invest Syd AB, Swedish Growth Fund and Sarah Fredriksson. The business concept is based on Professor Lars Edvinsson’s many years of research at Lund University investigating what happens in the blood vessels of the brain after a bleeding, leading to delayed cerebral ischemia. The result is the discovery of a novel first-in-class treatment, with great potential to minimize brain damage.
Company Details
- Employees
- 2
- Founded
- 2003
- Address
- Medicon Village, Scheelevägen 2,sweden
- Industry
- Biotechnology
- Website
- edvince.com
- Keywords
- Malmö.
- HQ
- Lund
Edvince Ab Questions
Edvince Ab's website is edvince.com
Edvince Ab's LinkedIn profile is https://se.linkedin.com/company/edvince-ab
Edvince Ab has
2 employees.
View email and phone details for 2
employees at Edvince Ab.
Edvince Ab's industry is
Biotechnology
Edvince Ab's top competitors are
Saga Diagnostics,
Targinta Ab,
Pharmnovo,
Synopsys Ab,
Aptahem,
Senabel,
Lithea Ab (Former Moroxite T Ab),
Etnomat,
Roots Of Malmö,
Coegin Pharma Ab.
Edvince Ab's categories are Biotechnology
Edvince Ab's founding year is 2003
